Actos Now for the prevention of diabetes (ACT NOW) study. - Wikidata - awgldk - TriplyDB

Actos Now for the prevention of diabetes (ACT NOW) study.

Actos Now for the prevention of diabetes (ACT NOW) study.

http://www.wikidata.org/entity/Q33488336

about

Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.Incretin therapy--present and future.Efficacy and Safety of Canagliflozin as Add-On Therapy to Metformin in Type 2 Diabetes Similarities and differences between patients included and excluded from a randomized clinical trial of vitamin D supplementation for improving glucose tolerance in prediabetes: interpreting broader applicability.Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review Advances in the treatment of prediabetes.Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance.Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk.Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Predi Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome.Pioglitazone: beyond glucose control.Oral anti-diabetic drugs for the prevention of Type 2 diabetes.Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM).Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?Pioglitazone Therapy and Fractures: Systematic Review and Meta-Analysis.Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.

P2860

Q24195168-EBEC02D7-84E2-49C4-8676-B5B56FE89109 Q24202245-11241720-43E9-41DA-A655-67D423971766 Q33880174-57BF9A4D-B4DD-4BE7-828E-EA02FAE0830E Q34139048-48E821D1-CED2-4095-A0A1-F16469F09170 Q34374321-BB891C41-63FB-4DF8-9F67-13E38D5385FB Q35578281-E391A9A9-F0E4-4FA7-9235-2F7F4E129D86 Q35760283-505F4291-402E-4D5C-B43A-5A7367A904FB Q35796638-516DFD44-FF35-4508-B6B0-60AE28059CE0 Q35853553-252A742D-2AD0-49CB-A686-B2E02C920470 Q36139056-E58EB74B-7E0C-45ED-BBE4-3BF62FD571A9 Q36327944-483EA064-6588-4F73-BAFE-40ACA7C9FE5F Q36386631-343E569E-B15B-4FA9-BA0F-440B8D213D1C Q36412515-D26BC39E-8712-4D4C-AA2A-2300E8EC8B53 Q37232313-C4AEF131-5C4E-4339-8DB9-95967C034B33 Q37251096-D07BA857-E7A4-4695-87E4-335FFFB15DDA Q37278256-B0D69FDD-3C8D-4ACA-9F9B-2426FCCF143D Q37537808-368C1E3E-BAE4-4009-A636-FFB5BF56C4D9 Q37606430-A99FC7FC-7F91-4AF9-96EE-88E71459F08C Q37607425-381E5C8C-5F8F-4E18-9EF3-94CD2202A003 Q37660219-258D3667-E287-424E-9FB0-B0C422FD5897 Q37750261-7B10CDB6-A070-45C1-BB4F-F4325C8D20AE Q37776510-BD39EF5E-F6C8-45BE-AFA4-5FBAA20C6DA9 Q37856436-92E1A9AB-E4F5-4178-823A-F7E9A9909AC5 Q37862131-EE9F0FD5-D96C-4C11-8357-B4DA39B3313B Q38092275-DE868B30-519C-460C-936C-8895B3AB16A7 Q39620719-78881DA3-8BE2-4F3B-BD2D-664D97CEA285 Q45340364-E6776255-52B2-41F4-91B5-B51850FCA6AB Q51382645-14049FCC-B44E-43F8-B008-69CA37AC6213 Q52570655-D9064372-F93F-4A00-92B0-80DCECD87288 Q53746829-5C21088F-A997-4E15-9027-37F08125A033

P2860

Actos Now for the prevention of diabetes (ACT NOW) study.

http://www.wikidata.org/entity/Q33488336

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Actos Now for the prevention of diabetes (ACT NOW) study.

@ast

Actos Now for the prevention of diabetes (ACT NOW) study.

@en

type

label

Actos Now for the prevention of diabetes (ACT NOW) study.

@ast

Actos Now for the prevention of diabetes (ACT NOW) study.

@en

prefLabel

Actos Now for the prevention of diabetes (ACT NOW) study.

@ast

Actos Now for the prevention of diabetes (ACT NOW) study.

@en

P1433

Q33488336-121B1C1F-10CB-49E4-84AD-1E968B4DA9DD

P1476

Q33488336-5AF1B38A-A236-4D76-BC15-5855F5CC8728

P2093

Q33488336-1FD2745F-5D33-4296-B524-7A2389052C87

Q33488336-2399278A-FF72-4E3D-8A0A-66F5C26A9EE2

Q33488336-266E66E6-5C8B-4E39-9016-5E5BD9B91468

Q33488336-31DF4B25-50E6-4905-AE97-CD156F1AA472

Q33488336-4A119004-C5DF-48A1-BD55-43A59408FD0A

Q33488336-5BDCD025-E9D0-4CB7-BEA7-B752FFDFD61F

Q33488336-B59388A3-3C48-48B3-BDAC-6CFFE3181565

Q33488336-BAFFBE46-F73C-4A0B-A413-83A448FDE1D4

Q33488336-CB1AAC7A-E7E7-46AE-9FDB-A38FF43F15C4

Q33488336-D3FAA908-E68C-4158-8AB2-F6986BFE855A

P2860

Q33488336-033838E4-578A-4E13-A2E5-8A28118DB5BC

Q33488336-07E47E5B-C02D-40E0-ABA7-8A312F311C57

Q33488336-08172311-81AE-41ED-A502-782F3AF207AB

Q33488336-131CB3BB-E64F-480E-BF13-CFBF1751DD97

Q33488336-2A18C66E-415F-4531-A2C4-465F0D7E552B

Q33488336-3879C566-4045-4AB3-9417-211553FC3777

Q33488336-3B30353B-BBB2-4A1A-A106-ED5AC711DC53

Q33488336-3D5A682D-FD38-4361-B725-FBD7EA1A5600

Q33488336-3E28AD9C-2B9A-4A51-87C1-7BE46CD7A729

Q33488336-41A1919F-B8E9-44D8-B88E-7FF07A98DA2B

P2888

Q33488336-4BA783A4-37AB-4771-A3C0-0E4A6C6243FC

P304

Q33488336-32EDAF65-3AFA-4502-8E39-BF55D55FB6C1

P31

Q33488336-DBA64A70-F733-402C-B2D3-2D40EFC5F2C2

P356

Q33488336-FCCF3E1D-A471-4C60-8668-ADB885534D78

P478

Q33488336-68FB8466-A517-4DB8-BE23-8C53A2163EBA

P50

Q33488336-9EFC9693-2E48-4985-903D-EE3688B13D3B

Q33488336-A7DB364A-C716-4E3A-8793-3098376C2D79

P577

Q33488336-63EB2406-EEE5-4AFB-923E-D34C39DCF449

P5875

Q33488336-5BA50D59-E750-4F30-821D-621EDBBF1DFA

P6179

Q33488336-D7FA4FB0-2858-4937-A0D7-ED489273EB0E

P698

Q33488336-88E9CE93-BCE5-46DF-BF58-C4C9A2A3B4F6

P932

Q33488336-E73DD6D9-D395-4EE1-BC2A-2A667C84CDD8

P356

P1433

BMC Endocrine Disorders

P1476

Actos Now for the prevention of diabetes (ACT NOW) study.

@en

P2093

Dawn Schwenke

http://www.w3.org/2001/XMLSchema#string

Devjit Tripathy

http://www.w3.org/2001/XMLSchema#string

Frankie B Stentz

http://www.w3.org/2001/XMLSchema#string

Maryann Banerji

http://www.w3.org/2001/XMLSchema#string

Nicolas Musi

http://www.w3.org/2001/XMLSchema#string

Peter D Reaven

http://www.w3.org/2001/XMLSchema#string

Ralph A Defronzo

http://www.w3.org/2001/XMLSchema#string

Robert R Henry

http://www.w3.org/2001/XMLSchema#string

Robert Ratner

http://www.w3.org/2001/XMLSchema#string

Stephen Clement

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

P2888

P304

17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1472-6823-9-17

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Abbas E Kitabchi

P577

2009-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26703092

http://www.w3.org/2001/XMLSchema#string

P6179

1045668457

http://www.w3.org/2001/XMLSchema#string

P698

19640291

http://www.w3.org/2001/XMLSchema#string

P932

2725044

http://www.w3.org/2001/XMLSchema#string